Comparison of generic (Rolexan) and brand (Clexan) forms of enoxaparin

Comparison of Anti Xa Activity of Rolexan Versus Clexane in critically ill patients with prophylactic doses

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016031910178N9

Enrollment

Registered

2016-06-09

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylaxis of deep vein thrombosis. Phlebitis and thrombophlebitis of other deep vessels of lower extremities

Interventions

Intervention 1: Enoxaparin (Rolexan) 40mg SC. Intervention 2: Enoxaparin (Clexane) 40 mg SC.

Treatment - Drugs

Enoxaparin (Rolexan) 40mg SC

Enoxaparin (Clexane) 40 mg SC

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18 years and older; Receiving enoxaparin with prophylactic dose Exclusion criteria: Patient participating in another study; Pregnant or lactating; Taking an anticoagulant in the last three months; Contraindication absolute and / or relative to the use of enoxaparin; Nobody wishing to participate in this study; Creatinine clearance less than 60ml/min

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measurment of anti Xa activity. Timepoint: Before and 4 hour after receiving enoxaparin. Method of measurement: Kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sistanizad

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences

sistanizadm@sbmu.ac.ir+98 218800087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026